Search results
Added:
3 years ago
A 2011 report from the American Heart Association states that “On the basis of 2007 mortality rate data, more than 2,200 Americans die of CVD every day, an average of 1 death every 39 seconds.”1 The economic cost of cardiovascular disease (CVD) in the US was nearly $286 billion in 2007, which is 15 % of total healthcare expenditure.
There are 13 million people living with a diagnosis of CVD.2…
View more
Added:
2 years ago
In this short interview from our coverage of the ACC.22 late-breaking trials, Dr Maura Marcucci (McMaster University, ON, CA) discusses a sub-study of the POISE-3 trial, which sought to evaluate the effects of a perioperative hypotension-avoidance strategy, compared to a hypertension-avoidance strategy in patients undergoing non-cardiac surgery (NCT03505723).
Discussion Points:
Study…
View more
The Role of Angiotensin Receptor Blockers in Cardiovascular Protection Beyond Blood Pressure Control
Added:
3 years ago
Article
Added:
1 year ago
TCT 22 - In this short video from TCT 2022, Dr Ajay Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, NY, US) joins us to discuss the findings of ReCor's RADIANCE II Pivotal trial, which aimed to evaluate the safety and effectiveness of the Paradise renal Denervation System in patients with stage 2 hypertension.
225 patients were randomized to receive either a renal…
View more
Added:
3 years ago
The lower level to which blood pressure should be taken and how soon treatment should be started are key considerations where aging and cardiovascular mortality risks are concerned. It has long been taught that blood pressure should be allowed to rise to a level deemed pre-hypertensive or hypertensive before non-pharmacological and pharmacological therapy is embarked upon. Is this really the…
View more
Added:
3 years ago
Introduction
The concept of 'hypertensionÔÇÖ as a clinical entity has been a work in progress for decades. At some point, the diagnosis of hypertension began to be linked to specific levels of blood pressure. The Joint National Committee (JNCI-JNC7) reports provide a perspective and an understanding that a clearer and precise definition might avoid the dead-end that the current concept of…
View more
Added:
2 years ago
In this short summary interview, Dr. Ajay Kirtane (Columbia University Medical Center, US) shares the six-month outcomes of a randomized trial of renal denervation (RDN) versus a sham procedure for resistant hypertension. The RADIANCE-TRIO Trial, presented first at TCT 2021, showed that the additional effects of pharmacologic intervention with maintenance of a BP-lowering effect of endovascular…
View more
Added:
3 years ago
The prevalence of hypertension is increasing. Most recently National Health and Nutrition Examination Survey (NHANES) 2003-2004 report showed that awareness of hypertension is quite high and increasing across all age and ethnic groups.1 Encouragingly, treatment and control are improving in the elderly population; however, treatment and control in younger age groups has not shown the same success…
View more
Added:
3 years ago
Hypertension is an important contributor to global morbidity and mortality and is a major burden on healthcare systems.1,2 More than 20% of the world’s population has high blood pressure when defined by conventional criteria: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.3,4 Even with therapeutic lifestyle and pharmacological measures, blood pressure remains poorly…
View more
Added:
1 year ago
In this short interview, Dr Ajay Kirtane (Columbia University Medical Center, US) shares the findings from a patient-level pooled analysis of Ultrasound RDN in radiance-HTN SOLO and Trio.
The analysis presented at EuroPCR 22 showed reductions in blood pressure in both cohorts at 6 months.
Discussion Points
1. Study Background
2. Study Design & Patient Selection Criteria
3. Key Results
4. Which…
View more
